Hubbry Logo
DiureticDiureticMain
Open search
Diuretic
Community hub
Diuretic
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Diuretic
Diuretic
Diuretic
View on Wikipedia
from Wikipedia
Diuretics
Drug class
Furosemide 125 mg vials for intravenous application
Class identifiers
UseForced diuresis, hypertension
ATC codeC03
External links
MeSHD004232
Legal status
In Wikidata

A diuretic (/ˌdaɪjʊˈrɛtɪk/ ⓘ) is any substance that promotes diuresis, the increased production of urine. This includes forced diuresis. A diuretic tablet is sometimes colloquially called a water tablet. There are several categories of diuretics. All diuretics increase the excretion of water from the body, through the kidneys. There exist several classes of diuretic, and each works in a distinct way. Alternatively, an antidiuretic, such as vasopressin (antidiuretic hormone), is an agent or drug which reduces the excretion of water in urine.

Medical uses

[edit]

In medicine, diuretics are used to treat heart failure, liver cirrhosis, hypertension, influenza, water poisoning, and certain kidney diseases. Some diuretics, such as acetazolamide, help to make the urine more alkaline, and are helpful in increasing excretion of substances such as aspirin in cases of overdose or poisoning. Diuretics are sometimes abused by athletes who seek to excrete water for quick weight loss and/or to mask their use of banned substances,[1] and by people with eating disorders, especially people with bulimia nervosa, who seek to lose weight.[citation needed]

The antihypertensive actions of some diuretics (thiazides and loop diuretics in particular) are independent of their diuretic effect.[2][3] That is, the reduction in blood pressure is not due to decreased blood volume resulting from increased urine production, but occurs through other mechanisms and at lower doses than that required to produce diuresis. Indapamide was specifically designed with this in mind, and has a larger therapeutic window for hypertension (without pronounced diuresis) than most other diuretics.[citation needed]

Types

[edit]

High-ceiling/loop diuretics

[edit]

High-ceiling diuretics may cause a substantial diuresis – up to 20%[4] of the filtered load of NaCl (salt) and water. This is large in comparison to normal renal sodium reabsorption which leaves only about 0.4% of filtered sodium in the urine. Loop diuretics have this ability, and are therefore often synonymous with high-ceiling diuretics. Loop diuretics, such as furosemide, inhibit the body's ability to reabsorb sodium at the ascending loop in the nephron, which leads to an excretion of water in the urine, whereas water normally follows sodium back into the extracellular fluid. Other examples of high-ceiling loop diuretics include ethacrynic acid and torasemide.[citation needed]

Thiazides

[edit]

Thiazide-type diuretics such as hydrochlorothiazide act on the distal convoluted tubule and inhibit the sodium-chloride symporter leading to a retention of water in the urine, as water normally follows penetrating solutes. Frequent urination is due to the increased loss of water that has not been retained from the body as a result of a concomitant relationship with sodium loss from the convoluted tubule. The short-term anti-hypertensive action is based on the fact that thiazides decrease preload, decreasing blood pressure. On the other hand, the long-term effect is due to an unknown vasodilator effect that decreases blood pressure by decreasing resistance.[5]

Carbonic anhydrase inhibitors

[edit]

Carbonic anhydrase inhibitors inhibit the enzyme carbonic anhydrase which is found in the proximal convoluted tubule. This results in several effects including bicarbonate accumulation in the urine and decreased sodium absorption. Drugs in this class include acetazolamide and methazolamide.[citation needed]

Potassium-sparing diuretics

[edit]

These are diuretics which do not promote the secretion of potassium into the urine; thus, potassium is retained and not lost as much as with other diuretics.[citation needed] The term "potassium-sparing" refers to an effect rather than a mechanism or location; nonetheless, the term almost always refers to two specific classes that have their effect at similar locations:

Calcium-sparing diuretics

[edit]

The term "calcium-sparing diuretic" is sometimes used to identify agents that result in a relatively low rate of excretion of calcium.[6]

The reduced concentration of calcium in the urine can lead to an increased rate of calcium in serum. The sparing effect on calcium can be beneficial in hypocalcemia, or unwanted in hypercalcemia.[citation needed]

The thiazides and potassium-sparing diuretics are considered to be calcium-sparing diuretics.[7]

  • The thiazides cause a net decrease in calcium lost in urine.[8]
  • The potassium-sparing diuretics cause a net increase in calcium lost in urine, but the increase is much smaller than the increase associated with other diuretic classes.[8]

By contrast, loop diuretics promote a significant increase in calcium excretion.[9] This can increase risk of reduced bone density.[10]

Osmotic diuretics

[edit]

Osmotic diuretics (e. g., mannitol) are substances that increase osmolarity, but have limited tubular epithelial cell permeability. They work primarily by expanding extracellular fluid and plasma volume, therefore increasing blood flow to the kidney, particularly the peritubular capillaries. This reduces medullary osmolality and thus impairs the concentration of urine in the loop of Henle (which usually uses the high osmotic and solute gradient to transport solutes and water). Further, the limited tubular epithelial cell permeability increases osmolality and thus water retention in the filtrate.[11]

It was previously believed that the primary mechanism of osmotic diuretics such as mannitol is that they are filtered in the glomerulus, but cannot be reabsorbed. Thus their presence leads to an increase in the osmolarity of the filtrate and to maintain osmotic balance, water is retained in the urine.[citation needed]

Glucose, like mannitol, is a sugar that can behave as an osmotic diuretic. Unlike mannitol, glucose is commonly found in the blood. However, in certain conditions, such as diabetes mellitus, the concentration of glucose in the blood (hyperglycemia) exceeds the maximum reabsorption capacity of the kidney. When this happens, glucose remains in the filtrate, leading to the osmotic retention of water in the urine. Glucosuria causes a loss of hypotonic water and Na+, leading to a hypertonic state with signs of volume depletion, such as dry mucosa, hypotension, tachycardia, and decreased turgor of the skin. Use of some drugs, especially stimulants, may also increase blood glucose and thus increase urination.[citation needed].

Low-ceiling diuretics

[edit]

The term "low-ceiling diuretic" is used to indicate a diuretic has a rapidly flattening dose effect curve (in contrast to "high-ceiling", where the relationship is close to linear). Certain classes of diuretic are in this category, such as the thiazides.[12]

Mechanism of action

[edit]

Diuretics are tools of considerable therapeutic importance. First, they effectively reduce blood pressure. Loop and thiazide diuretics are secreted from the proximal tubule via the organic anion transporter-1 and exert their diuretic action by binding to the Na(+)-K(+)-2Cl(-) co-transporter type 2 in the thick ascending limb and the Na(+)-Cl(-) co-transporter in the distal convoluted tubule, respectively.[13]

Classification of common diuretics and their mechanisms of action.
Class Examples Mechanism Location (numbered in distance along nephron)
Ethanol drinking alcohol Inhibits vasopressin secretion
Water Inhibits vasopressin secretion
Acidifying salts calcium chloride, ammonium chloride 1.
Arginine vasopressin
receptor 2 antagonists 		amphotericin B, lithium[14][15] Inhibits vasopressin's action 5. collecting duct
Selective vasopressin V2 antagonist (sometimes called aquaretics) tolvaptan,[16] conivaptan Competitive vasopressin antagonism leads to decreased number of aquaporin channels in the apical membrane of the renal collecting ducts in kidneys, causing decreased water reabsorption. This causes an increase in renal free water excretion (aquaresis), an increase in serum sodium concentration, a decrease in urine osmolality, and an increase in urine output.[17] 5. collecting duct
Na-H exchanger antagonists dopamine[18] Promotes Na+ excretion 2. proximal tubule[18]
Carbonic anhydrase inhibitors acetazolamide,[18] dorzolamide Inhibits H+ secretion, resultant promotion of Na+ and K+ excretion 2. proximal tubule
Loop diuretics bumetanide,[18] ethacrynic acid,[18] furosemide,[18] torsemide Inhibits the Na-K-2Cl symporter 3. medullary thick ascending limb
Osmotic diuretics glucose (especially in uncontrolled diabetes), mannitol Promotes osmotic diuresis 2. proximal tubule, descending limb
Potassium-sparing diuretics amiloride, spironolactone, eplerenone, triamterene, potassium canrenoate. Inhibition of Na+/K+ exchanger: Spironolactone inhibits aldosterone action, Amiloride inhibits epithelial sodium channels[18] 5. cortical collecting ducts
Thiazides bendroflumethiazide, hydrochlorothiazide Inhibits reabsorption by Na+/Cl− symporter 4. distal convoluted tubules
Xanthines caffeine, theophylline, theobromine Inhibits reabsorption of Na+, increase glomerular filtration rate 1. tubules

Caffeine when initially consumed in large quantities is both a diuretic and a natriuretic,[19] but this effect disappears with chronic consumption.[20][21][22]

Adverse effects

[edit]

The main adverse effects of diuretics are hypovolemia, hypokalemia, hyperkalemia, hyponatremia, metabolic alkalosis, metabolic acidosis, and hyperuricemia.[18]

Adverse effect Diuretics Symptoms
hypovolemia
hypokalemia
hyperkalemia
hyponatremia
metabolic alkalosis
metabolic acidosis
hypercalcemia
hyperuricemia

Abuse in sports

[edit]

A common application of diuretics is for the purposes of invalidating drug tests.[23] Diuretics increase the urine volume and dilute doping agents and their metabolites. Another use is to rapidly lose weight to meet a weight category in sports like boxing and wrestling.[24][25]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Diuretic

View on Grokipedia
from Grokipedia
A diuretic is a type of that promotes , the increased production of , primarily by inhibiting the of sodium and in the , leading to the excretion of excess fluid and electrolytes from the body. These agents work by targeting specific ion transport mechanisms along the , the functional unit of the , to disrupt the normal balance of sodium, , and . Diuretics are essential in managing fluid overload and are among the most commonly prescribed drugs worldwide due to their efficacy in reducing intravascular volume and alleviating associated symptoms. Diuretics are indicated for a range of edematous conditions, including , hepatic cirrhosis with , , and , where they help reduce swelling by promoting fluid removal. They are also used for non-edematous disorders such as , where they lower by decreasing blood volume and vascular resistance, often serving as a first-line . Additional applications include treating hypercalcemia, nephrolithiasis, and certain cases of , as well as facilitating the elimination of toxins in acute settings. While effective, their use requires monitoring for potential adverse effects, such as imbalances like or , , and metabolic disturbances. Diuretics are pharmacologically classified according to their primary site of action within the nephron and their specific mechanisms, which determine their potency and clinical utility. Loop diuretics, such as furosemide and bumetanide, act on the thick ascending limb of the loop of Henle by inhibiting the Na+-K+-2Cl- symporter, offering rapid and potent diuresis for acute conditions like heart failure exacerbations. Thiazide and thiazide-like diuretics, including hydrochlorothiazide and chlorthalidone, target the distal convoluted tubule via inhibition of the Na+-Cl- symporter and are preferred for long-term hypertension management due to their sustained effects. Potassium-sparing diuretics, such as spironolactone and amiloride, block sodium channels or aldosterone receptors in the collecting duct, minimizing potassium loss and often used in combination to counteract hypokalemia from other diuretics. Other classes include carbonic anhydrase inhibitors like acetazolamide, which reduce bicarbonate reabsorption in the proximal tubule and are mainly employed for glaucoma or altitude sickness, and osmotic diuretics such as mannitol, which draw water into the tubules osmotically for cerebral edema or acute renal failure. This classification guides therapeutic selection based on the patient's needs and the desired balance of efficacy and side effect profile.

Overview

Definition and Physiology

Diuretics are pharmacological agents that increase output by acting primarily on the kidneys to enhance the of water and s, thereby promoting through interference with renal tubular ion transport systems. This action helps regulate fluid and balance by reducing the of sodium and associated water in the . Normal renal physiology begins with glomerular filtration, where blood plasma is filtered in the glomerulus to form an ultrafiltrate at a rate of approximately 120–125 mL/min, driven by hydrostatic pressure across a semipermeable barrier consisting of fenestrated endothelium, basement membrane, and podocyte foot processes. The resulting filtrate then undergoes extensive tubular reabsorption along the nephron segments: the proximal convoluted tubule reabsorbs about 65–70% of filtered sodium, water, glucose, and amino acids via active transport mechanisms like the Na+/K+-ATPase pump; the loop of Henle, with its descending and ascending limbs, handles 20–25% of reabsorption, including water in the descending limb via aquaporins and ions like sodium, chloride, potassium, calcium, and magnesium in the ascending limb without water permeability; the distal convoluted tubule manages 5–10% of sodium and chloride reabsorption, regulated by hormones such as aldosterone and parathyroid hormone; and the collecting duct fine-tunes final sodium and water reabsorption under the influence of aldosterone and antidiuretic hormone (ADH), respectively. A core concept linking natriuresis (sodium excretion) to diuresis is that reduced tubular sodium reabsorption diminishes the osmotic gradient necessary for water reabsorption, thereby increasing urine volume; this relationship is captured in the basic physiological equation for urine output: Urine volume≈GFR−(reabsorbed water)\text{Urine volume} \approx \text{GFR} - \text{(reabsorbed water)} where GFR denotes glomerular filtration rate, highlighting how diuretics amplify excretion by targeting specific nephron sites to inhibit reabsorption. Effective diuretic action depends on physiological prerequisites such as adequate renal blood flow (typically 20–25% of cardiac output) and perfusion pressure (maintained between 80–180 mm Hg via autoregulation) to ensure filtrate delivery to the tubules and drug access to action sites.

Historical Development

The use of diuretic agents dates back to observations of natural substances with fluid-excreting properties. In the , mercury compounds such as (mercurous chloride) were employed to treat dropsy (), with physicians like William Stokes advocating their benefits in management until his death in 1878. Early in the , emerged as a recognized diuretic, introduced therapeutically in 1864 by Russian physician Ivan Koshiakoff for its ability to increase output, though its effects were modest compared to later developments. A significant advancement occurred in the with the introduction of organomercurial diuretics, which marked the first effective injectable agents for clinical use. In 1919, Alfred Vogl, a medical student at the , observed the potent diuretic effects of mercury-containing injections in patients, leading to the development of compounds like mersalyl; these were published in 1920 and rapidly adopted for treating in heart , hepatic cirrhosis, and over the next four decades.00130-6/fulltext) However, their requirement for intramuscular or intravenous administration, along with risks of , limited widespread outpatient application. The 1950s brought breakthroughs in oral diuretics, beginning with inhibitors derived from antibacterials. , synthesized in the late 1940s and introduced clinically around 1950, was the first such agent to demonstrate reliable diuretic effects in patients through case studies that highlighted its decongestive potential. This paved the way for diuretics, stemming from observations in 1937–1938 that s induced via renal mechanisms. In 1957, Karl H. Beyer Jr. and colleagues at Merck Sharp & Dohme synthesized chlorothiazide, the first orally effective diuretic, which received FDA approval that year for and , revolutionizing therapy by replacing cumbersome mercurials and enabling ambulatory treatment. The 1960s and 1970s saw further innovations, including like , patented in 1959 and introduced clinically in the mid-1960s after development in , offering superior potency for severe fluid overload. Potassium-sparing diuretics, such as —reported in 1959 by researchers at G.D. Searle & Co. and FDA-approved in 1960—emerged to counter imbalances from other agents, building on aldosterone antagonism research from the . Osmotic diuretics like , though observed earlier, gained refined clinical roles in this era for acute settings. The shift to oral formulations, exemplified by chlorothiazide, dramatically reduced hospital stays for by facilitating home management of . This historical progression laid the foundation for diuretics' integration into trials in subsequent decades.

Clinical Applications

Hypertension Management

Diuretics play a central role in management by primarily reducing through and , which acutely decreases and venous return; over time, this leads to a chronic reduction in total peripheral , resulting in a typical systolic drop of 10-15 mmHg with low-dose diuretics like hydrochlorothiazide. Major clinical trials have established the efficacy of diuretics in control and cardiovascular outcomes. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), published in 2002, demonstrated that chlorthalidone, a thiazide-like diuretic, was superior to lisinopril (an ) and amlodipine (a ) in preventing one or more major cardiovascular events, including and , in over 33,000 high-risk hypertensive patients, with similar reductions across arms but fewer adverse events like with the diuretic. Similarly, the Systolic Hypertension in the Elderly Program (SHEP) trial from 1991 showed that stepped-care therapy starting with low-dose (12.5-25 mg daily) reduced systolic by an average of 12 mmHg compared to placebo and lowered the risk of total by 36% in 4,736 elderly patients with isolated . Current guidelines endorse diuretics as first-line therapy for . The 2025 AHA/ACC guidelines recommend thiazide-type diuretics (e.g., or indapamide), long-acting , or ACE inhibitors/ARBs as initial treatment for adults with (BP ≥130/80 mmHg), particularly for Black adults or those with comorbidities like , , or , where they effectively reduce and risk. For example, hydrochlorothiazide is commonly dosed at 12.5-25 mg daily for , achieving effective control while minimizing side effects. Combination therapy enhances the antihypertensive effects of diuretics while addressing potential drawbacks. Pairing thiazides with ACE inhibitors or beta-blockers provides additive lowering—often achieving greater reductions than monotherapy—and mitigates diuretic-induced by attenuating renin-angiotensin-aldosterone system activation, as ACE inhibitors reduce aldosterone-mediated loss and beta-blockers blunt compensatory mechanisms. Meta-analyses, including the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) overview of 29 randomized trials, confirm that diuretic-based regimens reduce risk by 30-40% in hypertensive patients, underscoring their impact on long-term cardiovascular protection.

Edema and Fluid Overload

Diuretics play a central role in managing and fluid overload in conditions such as , liver , and renal diseases like and (CKD), primarily by promoting and reducing volume to alleviate symptoms like dyspnea, , and peripheral swelling. In , such as are the cornerstone for treating acute decompensated states, where intravenous administration is preferred for rapid onset, targeting a daily of 1-2 kg to achieve euvolemia without excessive or renal impairment. For patients transitioning from intravenous to oral therapy, a conversion ratio of approximately 2:1 (oral to intravenous) is often used, with initial oral doses of 40-80 mg twice daily for those not on chronic therapy, adjusted based on response and renal function. Approximately 50% of patients require chronic diuretic therapy to maintain symptom control and prevent recurrent hospitalizations. Recent guidelines, including updates as of 2025, integrate sodium-glucose cotransporter-2 (SGLT2) inhibitors, which may reduce diuretic requirements in management. In liver complicated by , a combination of and is recommended to prevent recurrence following initial , starting at a of 100 mg to 40 mg daily, with stepwise increases up to 400 mg and 160 mg respectively if needed, alongside sodium restriction. This regimen balances while enhancing , as targets distal sodium reabsorption and acts on the , per American Association for the Study of Liver Diseases (AASLD) guidelines. For and CKD, remain first-line for management, but (<2.5 g/dL) often leads to reduced drug delivery to the renal tubules, necessitating higher doses or co-administration with albumin infusions (e.g., 25% albumin preceding ) to improve oncotic pressure and diuretic efficacy. Close monitoring for resistance is essential, as declining glomerular filtration rate in CKD can impair response, requiring dose escalation or combination therapy. Clinical outcomes underscore the benefits of optimized diuretic strategies in these settings; for instance, in the PARADIGM-HF trial, sacubitril/valsartan combined with diuretics reduced loop diuretic requirements compared to enalapril, correlating with fewer heart failure hospitalizations. Diuretic resistance, defined as inadequate response despite escalating doses, affects up to 20-30% of patients and is managed through sequential nephron blockade, involving addition of thiazide or thiazide-like diuretics to loop agents to inhibit compensatory sodium reabsorption in distal segments. This approach, supported by combination therapy trials, enhances net sodium excretion by 20-50% in resistant cases, though it demands vigilant electrolyte and renal function monitoring to avoid complications like hypokalemia or worsening azotemia.

Other Therapeutic Uses

In the treatment of hypercalcemia, loop diuretics such as are employed after initial intravenous hydration to enhance urinary calcium excretion by inhibiting sodium and calcium reabsorption in the thick ascending limb of the loop of Henle. This approach is particularly useful in symptomatic patients or those with severe elevations in serum calcium levels, where it helps maintain euvolemia while promoting calciuresis. However, thiazide diuretics are contraindicated in hypercalcemia due to their enhancement of distal tubular calcium reabsorption, which can exacerbate the condition and lead to further increases in serum calcium. For nephrolithiasis associated with idiopathic hypercalciuria, thiazide diuretics like are indicated to prevent recurrent calcium stone formation by increasing renal calcium reabsorption and reducing urinary calcium excretion. According to the American Urological Association guidelines, these agents should be offered to patients with high or relatively high urine calcium and a history of recurrent stones, though a 2023 randomized trial found no significant benefit for in preventing recurrence compared to placebo. Older clinical trials suggested thiazide therapy could lower recurrence rates, potentially halving the risk over several years. Carbonic anhydrase inhibitors, such as acetazolamide, play a key role in managing acute angle-closure glaucoma by rapidly decreasing intraocular pressure through inhibition of aqueous humor production in the ciliary body. Administered intravenously or orally at doses of 500 mg initially followed by 250 mg every 6 hours, acetazolamide provides quick relief in emergency settings, often in combination with topical agents, until definitive laser or surgical intervention can be performed. In primary hyperaldosteronism, potassium-sparing diuretics like spironolactone are a cornerstone of medical therapy, acting as mineralocorticoid receptor antagonists to block aldosterone's effects on sodium retention and potassium excretion. This is especially relevant for bilateral adrenal hyperplasia, where surgery is not feasible, with typical dosing starting at 25-50 mg daily and titrated to normalize potassium and blood pressure while monitoring for side effects like gynecomastia. Spironolactone has shown superior efficacy over eplerenone in reducing blood pressure in these patients. Diuretics are also utilized in Meniere's disease to address endolymphatic hydrops, the presumed underlying pathophysiology involving excess fluid in the inner ear, by promoting diuresis and potentially reducing inner ear pressure. Low-evidence studies suggest oral diuretics, often combined with a low-sodium diet, may decrease the frequency of vertigo attacks, tinnitus, and hearing fluctuations, though high-quality randomized trials are lacking and Cochrane reviews indicate insufficient evidence for definitive efficacy. Recent investigations, including 2023 studies on combined therapies, have explored potassium-sparing diuretics like in polycystic ovary syndrome (PCOS) for their potential to reduce hyperandrogenism alongside anti-androgenic benefits. When added to , has demonstrated complementary effects in lowering hyperandrogenism markers and body mass index, though larger trials are needed to confirm these adjunctive roles.

Classification of Diuretics

Loop Diuretics

Loop diuretics, also known as high-ceiling diuretics, are a class of medications that inhibit the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle in the nephron. This inhibition prevents the reabsorption of approximately 20-25% of the filtered sodium load, leading to significant natriuresis and diuresis. The primary drugs in this class include furosemide, bumetanide, and torsemide, with furosemide being the most commonly used. Furosemide has an intravenous onset of action within 5 minutes, while oral administration takes 30-60 minutes; its duration of action is typically 4-6 hours. Bumetanide is more potent than furosemide, with equivalent doses of 1 mg bumetanide to 40 mg furosemide, and exhibits a similar onset but shorter half-life of about 1 hour. Torsemide, approximately twice as potent as furosemide (20 mg equivalent to 40 mg furosemide), offers a longer duration of 6-8 hours due to its extended half-life of 3-4 hours. These agents are sulfonamide derivatives, except for ethacrynic acid, which shares the class mechanism but lacks the sulfonamide structure. Oral bioavailability varies, with furosemide at around 50% (highly variable due to food and disease states), while bumetanide and torsemide achieve more consistent absorption of approximately 80%. Loop diuretics provide the greatest diuretic efficacy among classes, capable of inducing substantial fluid loss even in renal impairment where other diuretics fail, though their short duration necessitates frequent dosing. Furosemide was introduced in 1966, marking a pivotal advancement in diuretic therapy for acute fluid management. A unique risk associated with high doses is ototoxicity, particularly with rapid intravenous administration or in patients with renal dysfunction, potentially leading to temporary or permanent hearing loss.

Thiazide and Thiazide-like Diuretics

Thiazide and thiazide-like diuretics represent a class of agents with moderate natriuretic potency, primarily acting on the distal convoluted tubule to inhibit the sodium-chloride cotransporter (NCC), thereby blocking reabsorption of sodium and chloride ions. This mechanism results in the excretion of approximately 3-5% of filtered sodium, promoting diuresis and reduction in extracellular fluid volume while preserving the kidney's ability to concentrate urine. Unlike more potent diuretics, their effects are self-limiting due to compensatory sodium reabsorption in downstream nephron segments, making them ideal for chronic therapy in conditions requiring sustained but not aggressive fluid management. Structurally, thiazide-type diuretics feature a benzothiadiazine ring, a sulfonamide-containing scaffold that confers specificity for the NCC. Hydrochlorothiazide (HCTZ), the most commonly prescribed, is typically dosed at 25-50 mg daily; it achieves peak diuretic effect within 2-4 hours after oral administration and maintains activity for 6-12 hours, with a half-life of about 6-15 hours. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack this exact ring but share similar pharmacodynamic profiles while offering pharmacokinetic advantages. Chlorthalidone has a longer half-life of 40-60 hours, enabling once-daily dosing and more consistent 24-hour blood pressure control, which has led to its preference over HCTZ in numerous clinical trials demonstrating superior cardiovascular risk reduction. Indapamide, at doses of 1.25-2.5 mg, provides natriuresis alongside direct vasodilatory effects on vascular smooth muscle, potentially enhancing its antihypertensive efficacy through non-renal mechanisms. These diuretics exhibit optimal efficacy when glomerular filtration rate (GFR) exceeds 30 mL/min, as reduced renal function impairs delivery of the drug to its site of action in the distal tubule. In severe chronic kidney disease (GFR <30 mL/min), their natriuretic response diminishes, sometimes leading to paradoxical antidiuresis in scenarios involving associated polyuria, such as in polycystic kidney disease or nephrogenic diabetes insipidus. Discovered in 1957 through Merck's development of chlorothiazide—the first orally effective diuretic—these agents revolutionized hypertension treatment by offering a safe, affordable option that inhibits the renin-angiotensin-aldosterone system indirectly via volume depletion. Their cost-effectiveness remains a cornerstone of global hypertension control, with studies estimating annual healthcare savings in the millions when prioritized as first-line therapy over pricier alternatives. Thiazides promote kaliuresis, necessitating periodic electrolyte monitoring to mitigate hypokalemia risk.

Potassium-Sparing Diuretics

Potassium-sparing diuretics are classified into two main subtypes based on their mechanisms of action in the distal nephron, specifically the collecting duct. Aldosterone antagonists, such as spironolactone and eplerenone, competitively inhibit the mineralocorticoid receptor, thereby blocking the effects of aldosterone that promote sodium reabsorption and potassium secretion. In contrast, epithelial sodium channel (ENaC) inhibitors, including amiloride and triamterene, directly block ENaC in the luminal membrane of principal cells, reducing sodium entry and subsequent potassium excretion without interfering with aldosterone signaling. These agents exert their anti-mineralocorticoid effects primarily through modulation of ion transport in the late distal tubule and cortical collecting duct, preserving potassium while promoting natriuresis. The diuretic efficacy of potassium-sparing agents is mild, typically increasing fractional sodium excretion by approximately 2-3% of the filtered load, which accounts for the limited sodium reabsorption in the distal nephron under normal conditions. Their primary therapeutic value lies in counteracting potassium loss rather than robust volume reduction, making them suitable adjuncts to more potent diuretics like loops. For instance, spironolactone exhibits a short plasma half-life of about 1.6 hours, but its active metabolite canrenone extends the biological effect to around 16 hours, supporting once- or twice-daily dosing. Developed as a synthetic steroid derivative in the 1960s, spironolactone was among the first mineralocorticoid receptor antagonists introduced for clinical use. Eplerenone, a later nonsteroidal derivative, demonstrates greater selectivity for the mineralocorticoid receptor, resulting in fewer off-target endocrine effects such as antiandrogenic or progestational activity compared to spironolactone. Unique clinical considerations distinguish these agents; for example, spironolactone carries a notable risk of gynecomastia in men, occurring in up to 10% of users due to its cross-reactivity with androgen receptors, particularly at higher doses or prolonged exposure. The Randomized Aldactone Evaluation Study (RALES) trial in 1999 demonstrated spironolactone's beyond-diuretic benefits, showing a 30% reduction in all-cause mortality among patients with severe heart failure when added to standard therapy. They are often combined with loop diuretics to optimize potassium balance while augmenting overall natriuresis in conditions like heart failure.

Carbonic Anhydrase Inhibitors

Carbonic anhydrase inhibitors act primarily in the proximal tubule of the kidney, where they block the carbonic anhydrase enzyme responsible for catalyzing the conversion of carbonic acid to water and carbon dioxide. This inhibition impairs hydrogen ion (H+) secretion into the tubular lumen via the Na+/H+ exchanger and reduces bicarbonate (HCO3-) reabsorption, resulting in the urinary excretion of approximately 10% of the filtered NaHCO3 load. The primary drug in this class is acetazolamide, a sulfonamide derivative available in oral and intravenous formulations with a plasma half-life of 6-9 hours. Developed in the 1950s from sulfonamide compounds initially researched for glaucoma treatment, acetazolamide produces only mild diuresis associated with metabolic acidosis, which becomes self-limiting due to extracellular volume contraction and reduced delivery of filtrate to the proximal tubule. For diuretic purposes, doses typically range from 250 to 500 mg daily, often administered in divided doses. A distinctive feature of carbonic anhydrase inhibitors is their promotion of bicarbonate diuresis, which alkalinizes the urine by increasing HCO3- delivery to the distal nephron. Acetazolamide is also employed briefly in glaucoma management to decrease intraocular pressure through reduced aqueous humor formation.

Osmotic Diuretics

Osmotic diuretics are a class of agents that exert their effects through the osmotic properties of non-reabsorbable solutes, primarily acting within the renal tubules to promote water excretion. These compounds are freely filtered by the glomerulus but not reabsorbed by the tubular epithelium, thereby increasing the osmolality of the tubular fluid and creating an osmotic gradient that inhibits water reabsorption along the nephron. This mechanism draws water from the surrounding interstitium into the tubular lumen, resulting in increased urine volume and mild natriuresis, without directly interfering with ion transport mechanisms. The prototypical osmotic diuretic is mannitol, a six-carbon sugar alcohol administered intravenously as a 20% sterile solution, typically at doses of 0.5 to 1 g/kg over 30 to 60 minutes. Mannitol's administration leads to an initial expansion of the extracellular fluid volume as it draws water from intracellular spaces into the vascular compartment due to its hypertonicity, followed by osmotic diuresis as the solute is excreted. This biphasic effect was recognized in its development during the 1940s, when mannitol was identified for its diuretic potential following earlier explorations of hyperosmolar agents. An alternative osmotic diuretic, glycerol, can be given orally and serves as a less invasive option for similar indications, particularly in outpatient or pediatric settings. In terms of efficacy, osmotic diuretics like promote the excretion of approximately 10% of filtered sodium alongside substantial water loss, with diuresis onset occurring rapidly—within 30 minutes of intravenous administration—and peaking at 1 hour, with effects lasting 4 to 6 hours. This rapid action makes them particularly useful in scenarios requiring prompt volume reduction, such as oliguric acute kidney injury, where they help maintain urine output during the early phases. In neurosurgical contexts, uniquely reduces intracranial pressure by creating an osmotic gradient that dehydrates brain tissue, often achieving a 20-30% decrease in pressure to facilitate surgical access and mitigate cerebral edema.

Other Diuretics

Xanthines, such as caffeine and theophylline, function as mild diuretics primarily through non-selective antagonism of adenosine receptors in the kidneys. This antagonism inhibits adenosine-mediated vasoconstriction of afferent arterioles, thereby increasing glomerular filtration rate (GFR) and promoting natriuresis with approximately 1-2% of filtered sodium excreted. These effects result in a modest increase in urine output, though xanthines are not potent enough for primary therapeutic use in conditions like edema or hypertension. Herbal diuretics, including dandelion (Taraxacum officinale) and juniper (Juniperus communis), have been traditionally employed for their purported mild diuretic properties, often attributed to bioactive compounds like flavonoids and terpenes that may enhance renal perfusion or inhibit sodium reabsorption. However, these agents exhibit weak diuretic effects and suffer from a lack of standardization in dosing and preparation, leading to inconsistent outcomes. Studies from the 2020s, including systematic reviews of ethnopharmacological uses, indicate minimal efficacy in promoting significant diuresis or natriuresis compared to conventional diuretics, with limited high-quality clinical evidence supporting their use beyond supportive roles in mild fluid retention. Adrenergic agents like dopamine, when administered at low doses (0.5-2 μg/kg/min), primarily exert renal effects through stimulation of dopamine D1 and D2 receptors, causing vasodilation of renal arterioles and increased renal blood flow without qualifying as a true diuretic. This leads to enhanced GFR and some natriuresis, but the diuresis is secondary to hemodynamic changes rather than direct tubular inhibition, and clinical trials show no sustained improvement in renal function or protection against acute kidney injury. Low-ceiling diuretics, such as metolazone, are thiazide-like agents that act on the distal convoluted tubule to inhibit the sodium-chloride cotransporter, providing additive effects when combined with loop diuretics to overcome resistance in refractory edema. Metolazone's utility stems from its ability to block compensatory sodium reabsorption in the distal nephron, enhancing overall natriuresis in patients with heart failure or chronic kidney disease where loop diuretics alone prove insufficient. Diuretics also influence calcium handling differently based on their site of action, with implications for parathyroid hormone (PTH) modulation. Loop diuretics increase urinary calcium excretion by inhibiting the paracellular reabsorption pathway in the thick ascending limb, potentially elevating PTH levels to maintain serum calcium homeostasis. In contrast, thiazide diuretics promote calcium reabsorption in the distal convoluted tubule, reducing urinary losses and suppressing PTH secretion, which contributes to their bone-sparing effects observed in long-term use. Emerging diuretics include sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliflozin, which induce an osmotic diuresis through glycosuria by blocking glucose reabsorption in the proximal tubule, leading to natriuresis and modest fluid loss of about 1-2 kg. Reviews from the 2020s highlight their role in heart failure and chronic kidney disease management, where this mechanism not only aids decongestion but also provides nephroprotective benefits beyond traditional diuretics.

Pharmacology

General Mechanisms

Diuretics exert their effects primarily by inhibiting sodium reabsorption at specific sites along the nephron, resulting in increased urinary excretion of sodium and water. A common pathway across diuretic classes involves enhanced delivery of filtrate to the distal nephron, which stimulates sodium-potassium exchange in the cortical collecting duct via epithelial sodium channels (ENaC) and ROMK potassium channels, thereby increasing potassium (K+) and hydrogen ion (H+) excretion. This mechanism often leads to hypokalemia and metabolic alkalosis with prolonged use of sodium-reabsorbing inhibitors. The overall diuretic response can be expressed conceptually as Diuresis=f(Na delivery,transporter inhibition),\text{Diuresis} = f(\text{Na delivery}, \text{transporter inhibition}), where the magnitude of diuresis depends on the sodium load delivered to the site of transporter inhibition and the extent of that inhibition, with maximal natriuresis limited by compensatory reabsorption downstream. Synergistic effects arise when diuretics targeting different nephron segments are combined, such as loop diuretics acting on the thick ascending limb and distal diuretics (e.g., thiazides) on the distal convoluted tubule, through sequential blockade that prevents compensatory sodium reabsorption. This approach can more than double urinary sodium excretion compared to monotherapy, achieving fractional excretions exceeding 30% of filtered sodium in resistant cases, thereby enhancing net fluid removal. Diuretic resistance, defined as inadequate response despite escalating doses, stems from multiple factors including hypokalemia, which depletes intracellular potassium and impairs natriuretic signaling, leading to reduced efficacy (e.g., halving the response to loop diuretics in experimental models). Nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbate resistance by inhibiting renal prostaglandins, which are essential for maintaining afferent arteriolar dilation and diuretic secretion. Chronic use also triggers the braking phenomenon, characterized by post-diuretic sodium retention due to heightened distal reabsorption and a "memory effect" from prior volume contraction, limiting sustained natriuresis. Key delivery factors influencing diuretic efficacy include bioavailability, which varies widely (e.g., ~60% for oral furosemide with inter-subject differences from 10-100%), high plasma protein binding (e.g., >95% for furosemide, restricting free drug availability), and active tubular secretion via organic anion transporters (OAT1 and OAT3) in the , accounting for ~65% of furosemide's renal elimination. All oral diuretics depend on adequate glomerular filtration for initial renal handling, though predominates for many; intravenous administration is preferred in acute settings to bypass absorption variability and ensure prompt tubular delivery.

Pharmacokinetics and Administration

Diuretics exhibit variable pharmacokinetics across classes, influencing their clinical use in conditions such as and . Absorption primarily occurs via the for oral formulations, with differing notably among agents. For instance, like torsemide demonstrate near-complete oral of 68–100%, while shows more variable absorption at approximately 50%, and achieves 80–100%. diuretics, such as hydrochlorothiazide, have ranging from 55–77%. Food effects on absorption are generally minimal for most diuretics, though bioavailability may slightly decrease when taken with meals. Distribution of diuretics is characterized by high , limiting free drug availability. binds to approximately 94–96% of plasma proteins, primarily , while exhibits even higher binding exceeding 90%. Loop and diuretics generally have low volumes of distribution and cross the blood-brain barrier poorly, reducing effects. Metabolism and elimination pathways vary by class, affecting dosing frequency and duration of action. Potassium-sparing diuretics like spironolactone undergo hepatic metabolism to active metabolites, such as canrenone, with an elimination half-life of about 16 hours for the metabolite, despite the parent compound's short half-life of 1.4 hours. In contrast, thiazides like hydrochlorothiazide are primarily eliminated renally unchanged, with a half-life of 5.6–14.8 hours that prolongs in renal impairment. Loop diuretics show mixed elimination: furosemide is mostly renal (about 50% unchanged), with a half-life of 1.5–2 hours, whereas torsemide relies more on hepatic metabolism (80%), yielding a longer half-life of 3–4 hours. Administration strategies depend on the clinical scenario and diuretic class. Oral dosing is standard for chronic management, with based on response, while intravenous bolus administration of is preferred in acute settings like exacerbations for rapid onset (within minutes) and predictable . display a steep dose-response curve, where doubling the dose can substantially increase beyond a threshold, but a effect limits further gains. In , recent analyses highlight torsemide's pharmacokinetic advantages, including superior and longer , which may improve decongestion compared to , though large trials show mixed outcomes on mortality. Monitoring includes levels (e.g., , sodium) and renal function every 1–2 weeks initially during chronic therapy to guide adjustments and prevent imbalances.

Adverse Effects and Safety

Common Side Effects

Diuretics, by promoting the excretion of water and electrolytes, commonly lead to volume depletion, resulting in and . These effects manifest as symptoms including , , and , particularly upon standing, due to reduced intravascular volume. Management typically involves dose adjustment, monitoring fluid intake, and ensuring adequate hydration to prevent excessive loss. Hypokalemia, a reduction in serum levels, is a frequent adverse effect, especially with loop and diuretics, occurring in 20-50% of patients without potassium supplementation. This can cause , cramps, and cardiac arrhythmias, necessitating routine monitoring and often co-administration of potassium-sparing agents or supplements. predispose patients to this more than thiazides due to greater kaliuresis in the distal . Thiazide diuretics are particularly associated with , where serum sodium levels drop due to impaired free water excretion and potentiation of antidiuretic hormone effects. Risk factors include advanced age, female sex, and low , with elderly women being especially vulnerable. Symptoms range from mild to severe neurological disturbances, and early detection through serum checks is essential for reversal. Thiazide diuretics also elevate serum levels by 1-2 mg/dL through reduced renal urate clearance, potentially exacerbating in susceptible individuals. Additionally, they can induce glucose intolerance by promoting , partly via hypokalemia-induced inhibition of insulin release, which may worsen control in diabetic patients. These metabolic shifts highlight the need for baseline assessments in at-risk populations. Hypomagnesemia, often accompanying other electrolyte disturbances, contributes to muscle cramps and spasms in diuretic users, as magnesium loss impairs neuromuscular function. A proportion of patients may discontinue diuretics due to such side effects, underscoring the importance of replacement and periodic evaluation. Combining diuretics with alcohol can exacerbate common side effects, leading to severe dehydration due to the additive diuretic effects, amplified dizziness and low blood pressure (orthostatic hypotension), and worsened electrolyte imbalances such as hypokalemia, which may cause muscle cramps. Even over-the-counter or natural diuretics, such as those containing caffeine (e.g., coffee) or herbs like dandelion and parsley, can intensify these risks when mixed with alcohol.

Serious Risks and Contraindications

High-dose intravenous administration of , such as , can cause manifesting as reversible , particularly in patients with renal impairment or when co-administered with other ototoxic agents. The risk is heightened with concurrent use of antibiotics like gentamicin, which synergistically disrupt the blood-cochlear barrier, potentially leading to permanent damage through enhanced drug entry into structures. Potassium-sparing diuretics, including and amiloride, when combined with () inhibitors, increase the risk of , especially in patients, with an incidence of 5-10% in those on dual renin-angiotensin-aldosterone system (RAAS) blockade. may present with electrocardiographic changes such as peaked T waves, widened QRS complexes, and potentially life-threatening arrhythmias if serum exceeds 6.5 mEq/L. Over-diuresis with any class of diuretics can precipitate through pre-renal due to excessive volume depletion and reduced renal . This condition is characterized by a (BUN) to ratio greater than 20:1, reflecting disproportionate reabsorption in the proximal tubules amid . Absolute contraindications for diuretics include , as they offer no benefit and may worsen renal hypoperfusion, and hypersensitivity to sulfonamides for and certain like . Use in is relatively contraindicated due to potential risks of fetal disturbances, reduced placental , , and ; diuretics should be used only if the benefits outweigh the risks to the . Significant drug interactions include nonsteroidal anti-inflammatory drugs (NSAIDs), which blunt the natriuretic effects of loop and diuretics by inhibiting prostaglandin-mediated renal and may precipitate acute renal failure. diuretics can exacerbate by reducing its renal clearance through enhanced , necessitating close monitoring of levels. Additionally, spironolactone's anti-androgenic effects in males, such as and decreased , arise from blockade of testosterone synthesis and binding, occurring in a dose-dependent manner.

Non-Therapeutic Uses

Doping in Sports

Diuretics have been prohibited in sports since 1985 by the International Olympic Committee (IOC) and subsequently by the World Anti-Doping Agency (WADA), classified under S5 as diuretics and masking agents. This ban targets their dual misuse: rapid weight reduction and dilution of urine to conceal other prohibited substances like anabolic steroids by lowering their concentration below detectable thresholds. By increasing urine output, diuretics such as furosemide and hydrochlorothiazide reduce the specific gravity and volume of banned analytes, evading standard doping tests. In weight-class sports like wrestling, , and , athletes exploit diuretics to shed 5-10% of body weight quickly before weigh-ins, gaining a competitive edge by competing in lighter divisions after rehydration. This practice, often combined with fluid restriction and saunas, allows transient mass loss without long-term fat reduction, but it poses acute risks including severe that can lead to cardiovascular strain, thermoregulatory failure, and physical collapse during competition. Post-rehydration, performance suffers markedly; for instance, fluid deficits of 2-3% body mass can impair by up to 13% in time trials and halve overall exercise capacity in prolonged efforts. Detection relies on urine analysis where specific gravity below 1.005 (or 1.003 for samples ≥150 mL as of 2021) signals potential masking through dilution, prompting further scrutiny under WADA protocols that mandate a Minimum Reporting Level (MRL) of 20 ng/mL for several diuretics. Historical Olympic cases illustrate enforcement; since 1988, at least 11 athletes have been disqualified for furosemide use, primarily in weight-class events like weightlifting and taekwondo, with retesting of stored samples from prior Games uncovering additional violations. Although specific diuretic positives were less prominent at the 2016 Rio Olympics amid broader reanalysis efforts that sanctioned over 100 athletes for various prohibited substances, the system's focus on dilution thresholds continues to flag such misuse. IOC and WADA regulations prohibit all diuretic classes, including thiazides, loop agents, and inhibitors, with penalties for violations typically ranging from 2 to 4 years of ineligibility for first offenses, depending on intent and substance status as specified (e.g., potential reductions for ). Aggravating factors like evasion can extend bans to lifetime, as enforced through the , underscoring the principle where any presence constitutes a violation.

Weight Loss and Other Misuses

Diuretics are frequently misused for short-term by inducing , which results in the rapid elimination of water from the body rather than fat reduction. This practice is common in non-competitive communities, where individuals seek a leaner appearance for aesthetic purposes through temporary fluid loss. However, upon discontinuation, rebound sodium and water retention often occurs, leading to quick weight regain and potential exacerbation of fluid imbalances. Such yo-yo patterns from repeated misuse can contribute to increased cardiovascular risks, including and heart strain, due to chronic fluctuations in fluid volume and electrolytes. In the context of eating disorders, diuretic abuse is a prevalent purging method, affecting approximately 33% of individuals with or . Rates can reach up to 49% among those with specifically, often combined with abuse to counteract perceived calorie intake. This chronic misuse leads to severe disturbances, such as and , which heighten the risk of cardiac arrhythmias and long-term renal damage. Self-treatment with diuretics for conditions like bloating or (PMS) is another common , where individuals seek relief from perceived fluid retention without medical supervision. Although diuretics like may provide temporary symptom alleviation in documented cases of , routine is discouraged due to risks of deficiency, , and rebound fluid accumulation upon cessation. Herbal diuretics, such as those containing dandelion or , are particularly problematic as they remain unregulated by the FDA, potentially leading to inconsistent dosing, interactions with other medications, and undisclosed nephrotoxic effects. Epidemiological data from the 2020s indicate that about 2% of adolescents globally report lifetime use of nonprescription diuretics for , with higher rates among females influenced by body dissatisfaction and media pressures. This misuse is often part of broader unhealthy weight control behaviors, correlating with elevated risks of depression, substance use, and the development of full eating disorders. Beyond weight-related applications, historical misuse includes off-label self-administration of for prevention without proper or medical guidance, potentially causing unnecessary side effects like or in low-risk individuals. Over-the-counter (OTC) availability exacerbates these issues, as surveys show up to 87% of community pharmacists dispense diuretics without prescriptions, with 57% reporting purchases by apparently healthy individuals seeking fluid or . Such unregulated access heightens dangers like , manifesting as , dry mouth, and reduced urine output, underscoring the need for professional oversight.

Natural Diuretics in Beverages

Beverages incorporating natural diuretic components, such as those rich in potassium or containing saponins and yokuinin derived from Coix lachryma-jobi seeds, have been explored for their potential to promote the excretion of excess water and sodium, which may help relieve swelling associated with edema. Potassium in drinks like coconut water or certain herbal teas counteracts sodium retention by enhancing urinary output. Saponins, found in teas such as avocado leaf tea, exhibit diuretic effects by increasing urine volume and aiding in fluid elimination. Yokuinin, a traditional extract from Coix seeds, demonstrates diuretic and anti-inflammatory properties that support water excretion based on pharmacological studies. These actions are supported by general research on natural substances and are not intended as medical treatments; individuals should consult healthcare professionals for managing conditions like edema, as self-use may lead to imbalances or interactions.

Natural Diuretic Supplements

As of 2025, there is no single "best" diuretic supplement universally agreed upon for water retention, as effectiveness varies by individual, cause of retention, and formulation. However, dandelion root extract is one of the most commonly recommended and evidence-supported natural diuretic supplements. It has mild diuretic effects, is potassium-sparing (helping avoid electrolyte imbalance), and is frequently used for reducing bloating and mild edema. Other popular options include hibiscus, green tea extract, and horsetail, often found in blended "water pill" supplements. Always consult a healthcare professional before use, especially for persistent water retention, as it can indicate underlying conditions.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK557838/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9072265/
  3. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/diuretics/art-20048129
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9125415/
  5. https://www.ncbi.nlm.nih.gov/books/NBK538339/
  6. https://www.ncbi.nlm.nih.gov/books/NBK482248/
  7. https://pubsapp.acs.org/subscribe/archive/mdd/v06/i02/pdf/203timeline.pdf
  8. https://japi.org/article/japi-72-9-s1-11
  9. https://www.[researchgate](/page/ResearchGate).net/publication/282161041_Historical_and_contemporary_perspectives_of_diuretics_and_their_role_in_heart_failure_at_50_years_of_the_onset_of_furosemide_part_1_A_bit_of_history
  10. https://www.researchgate.net/publication/282161041_Historical_and_contemporary_perspectives_of_diuretics_and_their_role_in_heart_failure_at_50_years_of_the_onset_of_furosemide_part_1_A_bit_of_history
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10198661/
  12. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108565
  13. https://www.ahajournals.org/doi/pdf/10.1161/01.HYP.22.3.388
  14. https://www.jacc.org/doi/10.1016/j.jacc.2020.06.044
  15. https://www.acs.org/molecule-of-the-week/archive/s/spironolactone.html
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC10184374/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6730501/
  18. https://pubmed.ncbi.nlm.nih.gov/12479763/
  19. https://pubmed.ncbi.nlm.nih.gov/2046107/
  20. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
  21. https://www.mayoclinic.org/drugs-supplements/hydrochlorothiazide-oral-route/description/drg-20071841
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8673364/
  23. https://www.ajkd.org/article/S0272-6386%252821%252901019-2/fulltext
  24. https://www.jacc.org/doi/10.1016/j.jacc.2019.12.059
  25. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC10924023/
  27. https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.31884
  28. https://www.aasld.org/liver-fellow-network/core-series/why-series/why-do-we-use-combination-furosemide-and-spironolactone
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4695849/
  30. https://www.aafp.org/pubs/afp/issues/2016/0315/p479.html
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6607492/
  32. https://www.jacc.org/doi/10.1016/j.jacc.2010.06.034
  33. https://www.sciencedirect.com/science/article/pii/S2174204918303933
  34. https://emedicine.medscape.com/article/240681-treatment
  35. https://www.aafp.org/pubs/afp/issues/2003/0501/p1959.html
  36. https://blog.nus.edu.sg/phcdgs/2022/02/18/thiazide-diuretics-and-hypercalcaemia/
  37. https://www.auanet.org/guidelines-and-quality/guidelines/kidney-stones-medical-mangement-guideline
  38. https://www.nejm.org/doi/full/10.1056/NEJMoa2209275
  39. https://www.auajournals.org/doi/10.1016/j.juro.2014.05.006
  40. https://emedicine.medscape.com/article/1206956-treatment
  41. https://www.ncbi.nlm.nih.gov/books/NBK430857/
  42. https://primaryaldosteronism.org/medical-option/
  43. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.033597
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC8816439/
  45. https://emedicine.medscape.com/article/1159069-medication
  46. https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/0194599816630733
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC9007146/
  48. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1223768/full
  49. https://www.ncbi.nlm.nih.gov/books/NBK546656/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC4520883/
  51. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75d5611a-f9e0-1841-e053-2991aa0af415
  52. https://pubmed.ncbi.nlm.nih.gov/1712712/
  53. https://www.ncbi.nlm.nih.gov/books/NBK589894/table/michiganmedicine.t2/
  54. https://www.kidneynews.org/view/journals/kidney-news/17/4/article-p17_8.xml
  55. https://www.ncbi.nlm.nih.gov/books/NBK532918/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3350128/
  57. https://pubmed.ncbi.nlm.nih.gov/35404993/
  58. https://www.drugs.com/pro/hydrochlorothiazide.html
  59. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061029
  60. https://pubmed.ncbi.nlm.nih.gov/6352188/
  61. https://www.ahajournals.org/doi/10.1161/01.HYP.32.6.1071
  62. https://www.nature.com/articles/hr2012157
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12077745/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC201005/
  65. https://www.ncbi.nlm.nih.gov/books/NBK557736/
  66. https://abdominalkey.com/mechanisms-of-diuretic-action/
  67. https://www.ncbi.nlm.nih.gov/books/NBK532282/
  68. https://go.drugbank.com/drugs/DB00819
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC7794042/
  70. https://www.drugs.com/dosage/acetazolamide.html
  71. https://www.ncbi.nlm.nih.gov/books/NBK470392/
  72. https://pubmed.ncbi.nlm.nih.gov/6264198/
  73. https://pubmed.ncbi.nlm.nih.gov/6927604/
  74. https://www.ncbi.nlm.nih.gov/books/NBK519490/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC3275788/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6174542/
  77. https://www.ncbi.nlm.nih.gov/books/NBK223808/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC8468912/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC9375827/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC11054606/
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC7151902/
  82. https://www.ncbi.nlm.nih.gov/books/NBK535451/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC4419129/
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC3386653/
  85. https://www.ncbi.nlm.nih.gov/books/NBK534203/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC10500380/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC5933583/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC10126623/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5424889/
  90. https://pubmed.ncbi.nlm.nih.gov/3521452/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC8212983/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC9604628/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC10683075/
  94. https://pubs.acs.org/doi/10.1021/acsomega.0c03930
  95. https://www.ncbi.nlm.nih.gov/books/NBK589894/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC6682831/
  97. https://www.sciencedirect.com/science/article/pii/S0735109720301947
  98. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018225s024lbl.pdf
  99. https://go.drugbank.com/drugs/DB00421
  100. https://www.nature.com/articles/s41598-018-27995-w
  101. https://go.drugbank.com/drugs/DB00999
  102. https://www.ajkd.org/article/S0272-6386(21)01019-2/fulltext
  103. https://www.ncbi.nlm.nih.gov/books/NBK548808/
  104. https://pubmed.ncbi.nlm.nih.gov/33688065/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC12465095/
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC3041494/
  107. https://pubmed.ncbi.nlm.nih.gov/14631057/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4130802/
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC8672996/
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC8109617/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC11404643/
  112. https://www.healthline.com/health/furosemide-oral-tablet
  113. https://www.singlecare.com/blog/foods-to-avoid-when-taking-furosemide/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC6002634/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC7015190/
  116. https://www.ncbi.nlm.nih.gov/books/NBK560678/
  117. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020387s076lbl.pdf
  118. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018902s036lbl.pdf
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC4953490/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC2962812/
  121. https://www.science.org.au/curious/people-medicine/drugs-sport
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC8670259/
  123. https://www.ksep-es.org/journal/view.php?doi=10.15857/ksep.2020.29.3.300
  124. https://www.ukad.org.uk/news/urine-sample-concentration-change-come-effect-ahead-tokyo-games-what-means-athletes
  125. https://www.wada-ama.org/sites/default/files/resources/files/tl24_diuretics_eng_2021_0.pdf
  126. https://www.reuters.com/article/business/healthcare-pharmaceuticals/cas-dismisses-olympic-ban-on-doping-offenders-idUSTRE7953SQ/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC1112648/
  128. https://www.heart.org/en/news/2024/02/26/how-eating-disorders-can-damage-the-heart
  129. https://www.acute.org/resources/laxative-abuse-complications
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC4803618/
  131. https://www.mayoclinic.org/diseases-conditions/premenstrual-syndrome/diagnosis-treatment/drc-20376787
  132. https://www.ncbi.nlm.nih.gov/books/NBK279045/
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC10782242/
  134. https://www.usada.org/spirit-of-sport/acetazolamide/
  135. https://www.bibliomed.org/fulltextpdf.php?mno=104335
  136. https://www.healthline.com/nutrition/best-diuretic-foods-drinks
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC9262403/
  138. https://www.tuasaude.com/en/natural-diuretics/
  139. https://www.sciencedirect.com/science/article/abs/pii/S0924857998000788
  140. https://journals.sagepub.com/doi/10.1177/1934578X211048642
  141. https://www.medicalnewstoday.com/articles/313001
  142. https://pubmed.ncbi.nlm.nih.gov/19678785/
  143. https://www.healthline.com/nutrition/dandelion-benefits
  144. https://www.healthline.com/nutrition/natural-diuretics
Add your contribution
Related Hubs
User Avatar
No comments yet.